-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Overweight on Axsome Therapeutics, Raises Price Target to $255

Benzinga·05/05/2026 13:34:01
Listen to the news
Wells Fargo analyst Benjamin Burnett maintains Axsome Therapeutics (NASDAQ:AXSM) with a Overweight and raises the price target from $225 to $255.